ECHO-TEACH Talk, MD Anderson Cancer Center, February 7, 2017
|
|
- Carmella Jennings
- 6 years ago
- Views:
Transcription
1 Tobacco Treatment in People with Schizophrenia Tony P. George, MD, FRCPC Chief, Addictions Division, CAMH Professor and Co-Director, Division of Brain and Therapeutics, Department of Psychiatry, University of Toronto ECHO-TEACH Talk, MD Anderson Cancer Center, February 7, 2017
2 Learning Objectives: n Develop an evidence-based approach to assessment and treatment for tobacco use disorder in people with schizophrenia and other serious mental illness. n Understand an approach to developing a tobacco-free mental health and addictions facility for the benefit of patients, staff and visitors 3/30/2016 Slide 2
3 Medical Impact of Tobacco n Tobacco use is the leading cause of preventable death in Western world (Giovino, GA, 2007) n Over 470,000 deaths per year in USA and >50,000 annual deaths in Canada attributable to tobacco addiction (George, TP, Chapter 32, Cecil Textbook of Medicine, 25 th Edition) n Significant contributor to cardiovascular, pulmonary disease and to many cancers (e.g. lung, throat) (George, 2015) n Reducing smoking leads to some health improvements (e.g. better breathing and exercise tolerance), but reductions in cardiac, pulmonary and oncological disease are only seen when quitting smoking (George, 2015) Slide 3
4 Mental Health Impact of Tobacco n Higher rates of smoking in mentally ill (MI) populations makes them more vulnerable to tobacco-related medical illness (Mackowick et al., 2012) n People with MI spend up to 25% of their disability income on tobacco (Ziedonis et al., 2008) n Tobacco addiction shortens the lives of people with MI by years (Wiliams et al., 2011) n Rates of quitting smoking for MI smokers are 1/3 to 1/2 rates in the general population (Morisano et al., 2009) n Quitting smoking in MI populations leads to better psychiatric and substance use disorder outcomes, including reductions in depression and alcohol use, and less suicidal behaviours and aggression (Mackowick et al., 2012; Morozova et al., 2015) Slide 4
5 Prevalence of Tobacco Smoking in Clinical Samples of People with Mental Illness and Addictive Disorders Mean Smoking Prevalence (%) Schizophrenia Bipolar Disorder Major Depression Panic Disorder Post-Traumatic Stress Disorder Alcohol Dependence Cocaine Dependence Opioid Dependence General U.S. Population General Canadian Population Psychiatric Disorders SUD Non-PD Morisano, D., Bacher, I., Audrain-McGovern, J., George, T.P. (2009). Can. J. Psychiatry. 54: Slide 5
6 Current Smoking among Adults Aged 18 or Older Based on Serious Psychological Distress Status of Previous Month (NHIS, 1997 to 2011) Percent % *Difference between eskmate and eskmate for 2011 is strategically significant at the 0.5 level Slide 6
7 Tobacco Bans in Hospital Settings Advantages Disadvantages n Great opportunity to provide motivational interventions for those not initially willing to try to quit (a teachable moment ) n Reduction in episodes of seclusion and restraint, decreased PRN* use and Length Of Stay (LOS) n The goals of a smoke-free work environment are promoted and are consistent with wellness interventions that are being implemented in most inpatient settings n Inpatients generally not interested in quitting, as this is low on their hierarchy of needs n Staff are often reluctant as it can be perceived as a distraction to treatment plans, and is a critical positive reinforcer n Lack of training of unit staff or other qualified people to conduct smoking cessation counseling n Unmotivated inpatients pose a barrier to success of those few patients wanting to quit Lawn and Pols, 2005; Moss et al., 2010 Moss et al., Am. J. Addict *PRN Known as medicakons that are taken as needed Slide 7
8 Key Elements of Tobacco Free CAMH 1. No Smoking (or Vaping) at any campus site (2 main campuses + outpatient satellites) 2. No Possession of Tobacco Products on the Premises 3. Presence of Community Ambassadors, Patients and Staff who promote tobacco-free CAMH though a Wellness and Recovery Culture using a positive reinforcement approach and act as Champions for the Initiative Slide 8
9 Staff and Patient Attitudinal Survey Results n 10 % Staff Increase in staff confidence in having appropriate access to team / management support or training required to comply with the tobacco-free policy (12% to 22%) 7 % n Increase in awareness of how to help / where to refer a client if they want to quit (13% to 20%) Patient 19 % n Increase in the support of the creation of a tobacco-free policy at CAMH (48% to 67%) Pre-Launch N=454 Post-Launch N= % n Increase in the belief that lowering tobacco use on CAMH property is important (51% to 68%) 16 % n Increase in contributing to the success of the policy by not smoking at CAMH (56% to 72%) Pre-Launch N=123 Post-Launch N=106 Riad-Allen et al., Am. J. Addict., in press Slide 9
10 Effects of CAMH Tobacco Free on Aggression (Code Whites) *p<0.05 Riad-Allen, L. et al. (2017). Am. J. Addict., in press Slide 10
11 An approach to tobacco cessation in smokers with schizophrenia Slide 11
12 Quitting smoking is easy I ve done it several hundred times - Mark Twain
13 Case #1 n 40 year old black male with schizophrenia, never married, lives in a shelter in a major city. n Smokes 3 packs per day (illegal cigarettes), first cigarette is within 2 minutes of awakening. He also started smoking e-cigarettes ( Vapes ). n Multiple quit attempt failures since started smoking at age 14. Has tried all NRTs (gum, patch, inhaler) n Psychosis is well-managed with depot antipsychotic (Risperidone Consta), at 50 mg qmonth. Takes some oral risperidone for breakthru symptoms n Family Hx+ for CAD, Lung CA. He himself had anterior wall MI 6 months ago, after months of chest pain, took himself to local general hospital. n He doesn t really want to quit, but does not want to die from (another) MI
14 Question n What can we do for this man?
15 Vulnerability markers for tobacco addic4on in schizophrenia Wing, VC et al. (2012). Ann. NY Acad. Sci. 1249:
16 Reduced Smoking A Viable Target or Not? n Many smokers are simply unable to quit smoking. n Should sustained reductions in smoking been considered a goal of tobacco treatment or should reduction be a transitional goal towards eventual smoking abstinence (Hughes, 2002; George and Vessicchio, 2002; McChargue et al., 2002)? n A recent study suggests that sustained smoking reductions (50% reduction) do not reduce cancer or cardiac disease risk (Tverdall and Bjartveit, 2006).
17 Biobehavioural Vulnerability Factors to Tobacco Addic4on in Schizophrenia n Biochemical (reduced nachr levels, higher baseline nico8ne levels in Sz versus Controls) n Gene8c (α7 nachr, α3 nachr, COMT, DISC 1, Reelin) n Behavioral (deficits in reinforcement/reward) n Neurocogni8ve (neurophysiological/neuropsychological) Wing, VC et al., Ann. NY Acad. Sci
18 Lower β 2 *-nachrs in smokers with schizophrenia as compared to controls D Souza, DC, Esterlis, I. et al. (2012). Am. J. Psychiatry
19 Behavioral Factors Mecamylamine Effects on Reinforcement, Consump4on and Relapse Topography Puff Volume *p<0.05 vs. PLO * Consumption (Cigarettes/Session) *p<0.05 vs. PLO Smoking Cue-Reactivity *p<0.05 vs 10 mg/day McKee et al (2009). Schizophrenia Res. Weinberger et al (2007). Schizophrenia Res. Fonder et al. (2005). Biol. Psychiatry
20 George, T.P. et al., (2002). Neuropsychopharmacology 26: Effects of Abs4nence on Visuospa4al Working Memory (VSWM) in Smokers with Schizophrenia Distance From Target (cm) SCHIZOPHRENIA Quit Date Week in Trial 8 Abstinent Smoking 10 Distance From Target (cm) 1 0 CONTROLS n=23 n= Quit Date 2 4 Week in Trial 6 Abstinent Smoking 8
21 Selec4ve Enhancement of VSWM by CigareJe Smoking in Schizophrenia: Blockade by Mecamylamine * * p = vs. 5 mg/day * p < vs. 10 mg/day p < vs. CON Diagnosis x Dose: F=10.65, df=2,128, p<0.01 Sacco, K.A., Termine, A. et al. (2005). Arch. Gen. Psychiatry. 62:
22 Deficits in Frontal-Execu4ve Performance Predict Smoking Cessa4on Failure in Schizophrenia Schizophrenia p=0.052 Number of Seconds Trail Making Test - Part B p<0.05 Quit Not Quit Digit Quit Span Status Backward at Trial Endpoint Dolan, S.L., Sacco, K.A. et al., (2004). Schizophrenia Res. 70: Number of Digits Quit p<0.05 Quit Status at Trial Endpoint Moss, T.G. et al. (2009). Drug Alcohol Depend. 104: Not Quit
23 Cor4cal Dopamine Func4on and Spa4al SPATIAL WORKING MEMORY (%) Working Memory 4 Smoking SCHIZOPHRENIA 6 NORMAL 8 Smoking 10 CORTICAL DOPAMINE ACTIVITY STRESS George, T.P. et al., 2003, APPI
24 Atypical Versus Typical Antipsychotic Drugs and Nicotine Patch for Smoking Cessation in Schizophrenia (N=45) Smoking Abstinence Rate (%) * *p<0.05 vs. Typical * Atypical Typical Endpoint Last Four Weeks 6-Month F/U * George, T.P. et al. (2000). Am. J. Psychiatry. 157:
25 George, T.P., Vessicchio, J.C. et al. (2008). Biol. Psychiatry. 63: Combina4on of Transdermal Nico4ne and Bupropion SR is Superior to Placebo + Patch for Smoking Cessa4on in Schizophrenia (N=58) % Smoking Abstinence * Endpoint Abstinence * Continuous Abstinence 16 0 Six Month Abstinence Fisher s Exact Test + p = * p < 0.05 # p=0.11 # BUP Placebo
26 Varenicline (Champix ) n An α4β2-selective nachr partial agonist n Approved by the FDA in May, 2006 and by Health Canada in April, n In Phase III clinical trials, demonstrated superiority to both bupropion SR and placebo in continuous abstinence outcomes (Gonzalez et al., 2006, Jorenby et al., 2006) n Prevents smoking-relapse with treatment up to 24 weeks (Tonstad et al., 2006). n Dosing regimen is 0.5 mg qd x 3 days, then 0.5 mg bid x 4 days, then up to 1.0 mg bid for 12 weeks, with a label to extend treatment to 24 weeks as necessary.
27 Varenicline Side Effects n Main side effects are nicotine-like: Nausea (~30%), insomnia, headache and abnormal dreams. n Black Box warnings issued by FDA, Health Canada and EMEA regarding anecdotal reports of treatment-emergent suicidality, homocidality, aggression, psychosis and mania needs further study.
28 Cigarette Smoking, Cytochrome P450 and Psychotropic Drug Plasma Levels n Metabolized by CYP 1A2/3A4 n Not Metabolized n Clozapine n Olanzapine n Haloperidol n Chlorpromazine n Caffeine DeLeon, J. (2004). Psychiatric Serv. 55: n Risperidone n Ziprasidone n Aripiprazole n Quetiapine n Bupropion n SSRI s
29 Varenicline and Psychiatric Popula4ons n Several case reports both published (Freedman, 2007; Kohen and Kremen, 2007) and unpublished (FDA Medwatch) implica8ng varenicline in neuropsychiatric treatmentemergent adverse events (TEAEs), including suicidality, homicidality, psychosis and mania (O Malley, 2010). n However, clinical studies comparing Psychiatric Hx+ to Hx- smokers in varenicline treatment suggest that treatment outcomes and adverse events are comparable (e.g. Stapleton et al., 2008; McClure et al., 2010). n Recent controlled studies support its safety and efficacy in schizophrenia,, including in abs8nence-ini8a8on (Williams et al., J. Clin. Psychiatry; Anthenelli, RM et al Lancet) and relapse-preven8on (Evins et al., JAMA) studies. n Four studies suggests its safety and efficacy in smokers with bipolar disorder (Weinberger et al., 2008; Wu et al., 2012; Frye et al., 2013; Chengappa et al., 2014)
30 Varenicline for Smoking Cessa4on in People with Schizophrenia (N=127) Williams, J.M., Anthenelli, R.M., Morris, C., Tredow, J., Thompson, J.R., Yunis, C., George, T.P. (2012). J. Clin. Psychiatry. 73:
31 Varenicline Effects on Posi4ve and Nega4ve Symptoms in Smokers with Schizophrenia Williams, J.M. et al. (2012). J. Clin. Psychiatry.73:
32 Evins, AE et al., JAMA. 311:
33 EAGLES Study Randomized Comparison of Varenicline, Bupropion SR, Nicotine Patch and Placebo for Smoking Cessation in Mentally Ill versus Non-Mentally Ill Smokers (N=8144) Anthenelli, R.M. et al. (2016). Lancet. 387:
34 Ouellet-Plamondon, C. et al. (2014). Curr. Addict. Rep. 1:
35 Caroline Wass, Ph.D. r T M S epetitive ranscranial agnetic timulation n Stimulates the cortex by trains of magnetic pulses. n Frequencies of 1 to 50Hz n rtms has recently been used to treat neuropsychiatric disorders (e.g. depression, schizophrenia, parkinson s disease)
36 rtms reduces tobacco cravings in patients with schizophrenia TQSU score Factor 1 TQSU score Factor 2 3 Active rtms (n=4) 3 Active rtms (n=4) 2.5 Pre-rTMS Sham rtms (n=6) Post-rTMS 2.5 Pre-rTMS Sham rtms (n=6) Post-rTMS 5 Desire to Smoke 5 Anticipation of r elief from withdrawal after smoking TQSU score TQSU score Wing, VC et al, (2012) Schizophr. Res. 139: Pre-rTMS Active rtms (n=4) Sham rtms (n=6) Post-rTMS Pre-rTMS Active rtms (n=4) Sham rtms (n=6) Post-rTMS Anticipation of positive effects of smoking Intention to Smoke TQSU score TQSU score Active rtms (n=4) 3.5 Active rtms (n=4) 2.5 Pre-rTMS Sham rtms (n=6) Post-rTMS 3 Pre-rTMS Sham rtms (n=6) Post-rTMS
My Mask. I keep it all inside. Because I d rather. The pain destroy me. Than everyone else. Anon.
My Mask KL I keep it all inside Because I d rather The pain destroy me Than everyone else. Anon. 43 K. N. Roy Chengappa, M.D., FRCPC Professor of Psychiatry, University of Pittsburgh School of Medicine,
More informationPharmacological Treatments for Tobacco Users with Behavioral Health Conditions
Pharmacological Treatments for Tobacco Users with Behavioral Health Conditions Jill M Williams, MD Professor Psychiatry Director, Division Addiction Psychiatry Robert Wood Johnson Medical School Disclosures
More informationChantix Label Update 2018
Chantix Label Update 2018 Chantix (varenicline) Prescribing Information Chantix Prescribing Info URL and Disclaimer Please refer to the full Prescribing Information on important treatment considerations
More information9/16/2016. I would feel comfortable dispensing/prescribing varenicline to a patient with a mental health disorder. Learning Objectives
The Smoking Gun: for Smoking Cessation in Patients with Mental Health Disorders BRENDON HOGAN, PHARMD PGY2 PSYCHIATRIC PHARMACY RESIDENT CTVHCS, TEMPLE, TX 09/23/2016 I would feel comfortable dispensing/prescribing
More informationSmoking Cessation. Disclosures. Thank You. None
Smoking Cessation Dr. Jamie Kellar; BSc, BScPhm, PharmD Clinician Educator Centre for Addiction and Mental Health Assistant Professor Leslie Dan Faculty of Pharmacy Disclosures None Thank You Several slides
More informationStrategies for Integrating Smoking Cessation & Wellness into Psychiatric & Substance Abuse Treatment Settings
Strategies for Integrating Smoking Cessation & Wellness into Psychiatric & Substance Abuse Treatment Settings Antoine Douaihy, MD Associate Professor of Psychiatry University of Pittsburgh School of Medicine
More informationPHARMACOTHERAPY OF SMOKING CESSATION
PHARMACOTHERAPY OF SMOKING CESSATION Domenic A. Ciraulo, MD Director of Alcohol Pharmacotherapy Research Center for Addiction Medicine Department of Psychiatry Massachusetts General Hospital Disclosure
More informationVarenicline Update. Serena Tonstad, MD, PhD Dept of Preventive Cardiology Ullevål University Hospital Oslo, Norway
Varenicline Update Serena Tonstad, MD, PhD Dept of Preventive Cardiology Ullevål University Hospital Oslo, orway October 23, 2015 Disclosures related to smoking cessation: Pfizer, Mceil, ovartis Binding
More informationVarenicline and Other Pharmacotherapies for Tobacco Dependence
Varenicline and Other Pharmacotherapies for Tobacco Dependence J. Taylor Hays, M.D. Associate Director Nicotine Dependence Center Mayo Clinic 2012 MFMER slide-1 Learning Objectives Understand the mechanism
More informationEffective Treatments for Tobacco Dependence
Effective Treatments for Tobacco Dependence Abigail Halperin MD, MPH Director, University of Washington Tobacco Studies Program Ken Wassum Associate Director of Clinical Development and Support Quit for
More informationTony Klein, MPA, CASAC, NCACII
Tony Klein, MPA, CASAC, NCACII Presentation Overview Tobacco Dependence in Individuals with Co-occurring Addictions Challenges and Barriers Organizational Change Strategies Program & System Changes to
More information3. Chantix [package insert]. New York, NY: Pfizer, Inc,; Ramon JM, Morchon S, Baena A, Masuet-Aumatell C. Combining varenicline and nicotine
How can there be a warning regarding concomitant use of varenicline with nicotine replacement therapy yet patients can be on varenicline and smoke concurrently? April 20, 2017 The United States (US) Preventive
More informationAn Evolving Perspective on Smoking Cessation Therapies
An Evolving Perspective on Smoking Cessation Therapies Andrew Pipe, CM, MD Chief, Division of Prevention & Rehabilitation University of Ottawa Heart Institute Faculty/Presenter Disclosure Andrew Pipe,
More informationTobacco treatment for people with serious mental illness (SMI)
Tobacco treatment for people with serious mental illness (SMI) An opportunity to close the mortality gap Massachusetts Mental Health Center 1 National Resource Center for Academic Detailing A compelling
More informationTobacco Use Dependence and Approaches to Treatment
University of Kentucky UKnowledge Nursing Presentations College of Nursing 11-2011 Tobacco Use Dependence and Approaches to Treatment Audrey Darville University of Kentucky, audrey.darville@uky.edu Chizimuzo
More informationSMOKING CESSATION WORKSHOP. Dr Mark Palayew December
SMOKING CESSATION WORKSHOP Dr Mark Palayew December 5 2016 Conflicts of Interest None Case 1 Mr. T is a 55 year old smoker 2 packs/day He has been smoking continuously since age 16 When he wakes up at
More informationSession 8: Tobacco Interventions for Patients with Mental Health Issues
Tobacco Cessation Interventions Lunch and Learn Seminar Series for Physicians, Family Health Teams, and other Health/Allied Health Practitioners Session 8: Tobacco Interventions for Patients with Mental
More informationHelping People Quit Tobacco
Helping People Quit Tobacco Peter Selby MBBS, CCFP, MHSc, ASAM Associate Professor, University of Toronto Clinical Director, Addictions Program, CAMH Principal Investigator, OTRU Disclosures! Grants/research
More informationTreatment of Tobacco and Cocaine Use Disorders
Treatment of Tobacco and Cocaine Use Disorders A. Eden Evins, MD, MPH Director, Center for Addiction Medicine Massachusetts General Hospital Associate Professor of Psychiatry Harvard Medical School A.
More informationTreatment of Tobacco and Cocaine Use Disorders
Treatment of Tobacco and Cocaine Use Disorders A. Eden Evins, MD, MPH Director, Center for Addiction Medicine Massachusetts General Hospital Associate Professor of Psychiatry Harvard Medical School A.
More informationUpdate on Medications for Tobacco Cessation
Update on Medications for Tobacco Cessation Marc Fishman MD Johns Hopkins University Dept of Psychiatry Maryland Treatment Centers Baltimore MD MDQuit Best Practices Conference Jan 2013 Nicotine Addiction
More informationEMERGING ISSUES IN SMOKING CESSATION
EMERGING ISSUES IN SMOKING CESSATION Andrew Pipe, CM, MD Chief, Division of Prevention & Rehabilitation University of Ottawa Heart Institute Faculty/Presenter Disclosure Andrew Pipe, CM, MD University
More informationSupporting smokers with mental health problems
Collaboration for Leadership in Applied Health Research and Care South London (CLAHRC South London) Supporting smokers with mental health problems Ann McNeill, Professor of Tobacco Addiction Dr Debbie
More informationSmoking Still Kills! (Figs for England)
Smoking Cessation Gay Sutherland (Clinical Psychologist) Visiting Researcher - Tobacco Research Unit Inst. of Psychiatry, Psychology & Neuroscience King s College London Smoking Still Kills! (Figs for
More informationBackground. Abstinence rates associated with varenicline
What are the range of abstinence rates for varenicline for smoking cessation? Do they differ based on treatment duration? Are there any studies utilizing 3-4 months of varenicline treatment? Background
More informationSmoking Cessation: Where Are We Now? Nancy Rigotti, MD
Smoking Cessation: Where Are We Now? Nancy Rigotti, MD Director, MGH Tobacco Research and Treatment Center Professor of Medicine, Harvard Medical School nrigotti@partners.org OVERVIEW The challenge for
More informationPharmacotherapy Summary for the Treatment of Nicotine Withdrawal and Nicotine Dependence 1
Pharmacotherapy Summary for the Treatment of Nicotine Withdrawal and Nicotine Dependence 1 Compiled by: TOP, in collaboration with Dr. Charl Els and Mr. Ron Pohar: TRaC II (Alberta Medical Association/Primary
More informationTreating Tobacco Use:
Treating Tobacco Use: Optimizing for the Best Outcomes Nancy Rigotti, MD Director, MGH Tobacco Research and Treatment Center Professor of Medicine, Harvard Medical School nrigotti@partners.org Primary
More informationTreatment Outcomes from the TDC: A Look at Smoking Cessation Among Patients with Co- Occurring Disorders
University of Kentucky From the SelectedWorks of Chizimuzo T.C. Okoli December, 2010 Treatment Outcomes from the TDC: A Look at Smoking Cessation Among Patients with Co- Occurring Disorders Chizimuzo T.C.
More informationTobacco Dependence Treatment From Neurobiology through Public Policy
Tobacco Dependence Treatment From Neurobiology through Public Policy Mary Ellen Wewers, PhD, MPH, RN Professor Emerita The Ohio State University College of Public Health Disclosures Funding from the National
More informationBest Practice for Smoking Cessation: Pharmacotherapy. Emma Dean Acting Population Health and Health Promotion Coordinator Lead Pharmacist- Smokefree
Best Practice for Smoking Cessation: Pharmacotherapy Emma Dean Acting Population Health and Health Promotion Coordinator Lead Pharmacist- Smokefree Why is it so hard to quit? People who smoke aren t weak
More informationUpdates in the Treatment of Tobacco Use Disorder
Updates in the Treatment of Tobacco Use Disorder Jill M Williams, MD Professor Psychiatry Director, Division Addiction Psychiatry Robert Wood Johnson Medical School Disclosures Grant Support from Pfizer
More informationPharmacotherapy for Tobacco Dependence Treatment
Pharmacotherapy for Tobacco Dependence Treatment Nancy Rigotti, MD Professor of Medicine, Harvard Medical School Director, Tobacco Research and Treatment Center, Massachusetts General Hospital nrigotti@partners.org
More informationPharmacologic Therapy for Tobacco Use & Dependence
Pharmacologic Therapy for Tobacco Use & Dependence Thomas Gauvin, MA, TTS Mayo Clinic Nicotine Dependence Center Rochester, MN 2013 MFMER slide-1 Learning Objectives Understand the 7 first line medications
More informationDrug Use Evaluation: Smoking Cessation
Drug Use Research & Management Program Oregon State University, 3303 SW Bond Av CH12C, Portland, Oregon 97239-4501 Phone 503-947-5220 Fax 503-494-1082 Drug Use Evaluation: Smoking Cessation Tobacco cessation
More informationProject TEACH. Smoking Cessation For People With Schizophrenia. Maher Karam Hage, MD Professor, Depts. Of Behavioral Science and Psychiatry
Project TEACH Smoking Cessation For People With Schizophrenia Maher Karam Hage, MD Professor, Depts. Of Behavioral Science and Psychiatry Outline 1) What is behind the high comorbidity between Schizophrenia
More informationComplex Mental Illness and Concurrent Addictions
Complex Mental Illness and Concurrent Addictions Tony P. George, M.D., FRCPC Professor of Psychiatry Co Director, Division of Brain and Therapeutics Department of Psychiatry, University of Toronto Chief,
More informationSmoking cessation and reduction in people with chronic mental illness
Link to this article online for CPD/CME credits Smoking cessation and reduction in people with chronic mental illness Center for Alcohol and Addiction Studies, Brown University, Providence, RI 02912, USA
More informationButt in: Support for patients who smoke
Butt in: Support for patients who smoke Emma Dean Acting Population Health and Health Promotion Coordinator Lead Pharmacist- Smokefree May 2018 Disclosures In relation to this presentation, I declare the
More informationIndividuals with Psychiatric and Substance Use Disorders Comprise an Important Segment of Smokers & Consume Nearly 1 in 2 Cigarettes Sold
Introducing the EAGLES Trial: Its Purpose, Findings & Implications Robert M. Anthenelli, M.D. Professor and Executive Vice Chair Director, Pacific Treatment and Research Center Department of Psychiatry
More informationKeywords: tobacco, cigarette smoke, nicotine, dopamine, smoking cessation, acethylcholine, varenicline (champix )
Review Article and Clinical Experience: ENICLINE (CHAMPIX ) : A BREAKTHROUGH FOR SMOKING CESSATION TREATMENT (An α4ß2 Nicotinic Acethylcholine Receptor Partial Agonist) Askandar Tjokroprawiro Diabetes
More informationHow best to get your patients to stop smoking. Dr Alex Bobak GP and GPSI in Smoking Cessation Wandsworth, London
How best to get your patients to stop smoking Dr Alex Bobak GP and GPSI in Smoking Cessation Wandsworth, London 1 2 Smoking can cause at least 14 different types of cancer 3 Smokers want to stop All smokers
More informationTOBACCO CESSATION: INCORPORATING MOTIVATIONAL INTERVIEWING AND EXAMINING THE ROLE OF E-CIGS
Learning Objectives TOBACCO CESSATION: INCORPORATING MOTIVATIONAL INTERVIEWING AND EXAMINING THE ROLE OF E-CIGS Cheyenne Newsome, PharmD PGY2 Ambulatory Care Resident University of New Mexico College of
More informationButt in to Butt Out- Pharmacist led clinical model for managing nicotine dependency
Butt in to Butt Out- Pharmacist led clinical model for managing nicotine dependency Emma Dean Acting Population Health and Health Promotion Coordinator Alfred Health Wednesday 30 th May 2018 2 Disclosures
More informationUPDATE TREATMENT OF TOBACCO USE DISORDERS
Psychiatry and Addictions Case Conference UW Medicine Psychiatry and Behavioral Sciences UPDATE TREATMENT OF TOBACCO USE DISORDERS MARK DUNCAN MD UNIVERSITY OF WASHINGTON OBJECTIVES 1. Remind everyone
More informationWelcome and Webinar Logistics
Welcome and Webinar Logistics We recommend calling in on your telephone Remember to enter your Audio PIN so we can unmute your line when you have a question Audio PIN: Will be displayed after you login
More informationSMOKING CESSATION IS HARD
POWER TO BREAK THE HOLD OF NICOTINE ADDICTION 1 SMOKING CESSATION IS HARD Most smokers try to quit 5-7 times before they are successful. 2 Why is it so hard to quit? Typical withdrawal symptoms from stopping
More informationHIV and Aging. Making Tobacco Cessation a Priority in HIV/AIDS Services. Objectives. Tobacco Use Among PLWHA
HIV and Aging Making Tobacco Cessation a Priority in HIV/AIDS Services June 27, 2008 Amanda Brown, MPH Ruth Tripp, MPH, RN Objectives To explore existing knowledge of the HIV and smoking connection. To
More informationTOBACCO CESSATION: INCORPORATING MOTIVATIONAL INTERVIEWING AND EXAMINING THE ROLE OF E-CIGS
TOBACCO CESSATION: INCORPORATING MOTIVATIONAL INTERVIEWING AND EXAMINING THE ROLE OF E-CIGS Cheyenne Newsome, PharmD PGY2 Ambulatory Care Resident University of New Mexico College of Pharmacy Learning
More informationAddressing Smoking Among Individuals with Behavioral Health Issues
Addressing Smoking Among Individuals with Behavioral Health Issues Carlo C. DiClemente, Ph.D. Director of MDQuit Janine C. Delahanty, Ph.D. Associate Director of MDQuit MHA Annual Conference May 4, 2011
More informationProject ECHO Importance of Treating Tobacco Use In People With Behavioral Health Disorders Jan Blalock, Ph.D.
Project ECHO Importance of Treating Tobacco Use In People With Behavioral Health Disorders Jan Blalock, Ph.D. High Levels Of Tobacco Use Almost twice as likely to smoke as people without disorders (36.1%
More informationBreaking the Chains of Nicotine Dependence - A Breakthrough Approach
Breaking the Chains of Nicotine Dependence - A Breakthrough Approach Dr Rob Young Senior Lecturer & Consultant Physician Auckland Hospital, New Zealand Smoking Cessation in 2001 Smoking contributes to
More informationBrief Intervention for Smoking Cessation. National Training Programme
Brief Intervention for Smoking Cessation National Training Programme Introduction Monitor tobacco use and prevention policies Protect people from tobacco smoke Offer help to quit tobacco use Warn about
More informationSmoke-free Hospitals. Linda A. Thomas, MS University of Michigan Health System Tobacco Consultation Service
Smoke-free Hospitals Linda A. Thomas, MS University of Michigan Health System Tobacco Consultation Service Today s Subjects 5A s and Clinician Training and Use with the Hospitalized Patient NRT use in
More informationSMOKING CESSATION. Recommendations 5As Approach to Smoking Cessation. Stages of Change Assisting the Smoker. Contributor Dr. Saifuz Sulami.
SMOKING CESSATION 08 Recommendations 5As Approach to Intervention Stages of Change Assisting the Smoker Pharmacotherapy Contributor Dr. Saifuz Sulami Advisor Dr. Audrey Tan 79 nhg_guideline_14102010_1112.indd
More informationPharmacotherapy Safety and Efficacy in Adolescent Smoking Cessation
Philadelphia College of Osteopathic Medicine DigitalCommons@PCOM PCOM Physician Assistant Studies Student Scholarship Student Dissertations, Theses and Papers 2011 Pharmacotherapy Safety and Efficacy in
More informationSmoking Cessation for Persons with Serious Mental Illness
Smoking Cessation for Persons with Serious Mental Illness MDQuit Best Practices Conference January 22, 2009 Faith Dickerson, Ph.D., M.P.H. Sheppard Pratt Health System Lisa Dixon, M.D., M.P.H. Melanie
More informationIf treatment for tobacco addiction was evidence-based, what would it look like? Robert West University College London YORK, November 2005
If treatment for tobacco addiction was evidence-based, what would it look like? Robert West University College London YORK, November 2005 Outline What is tobacco addiction and what is the goal of treatment?
More informationSECTION 17: NICOTINE REPLACEMENT. Formulary and Prescribing Guidelines
SECTION 17: NICOTINE REPLACEMENT Formulary and Prescribing Guidelines 17.1 Introduction These guidelines should be used in conjunction with EPUT No Smoking Policy (HRP20) for service users who are 12 years
More informationPharmacotherapy for Treating Tobacco Dependence
Pharmacotherapy for Treating Tobacco Dependence Sheila K. Stevens, MSW Education Coordinator Nicotine Dependence Center 2013 MFMER slide-1 Rationale for Pharmacological Therapy Success rate doubles Manage
More informationTreatment of Tobacco Dependence in Mental Health and Addictive Disorders
Treatment of Tobacco Dependence in Mental Health and Addictive Disorders Brian Hitsman, PhD 1 ; Taryn G Moss, BA 2 ; Ivan D Montoya, MD, MPH 3 ; Tony P George, MD, FRCPC 4 People with mental health and
More informationPrepared by: Dr. Elizabeth Woodward, University of Toronto Resident in Psychiatry
Prepared by: Dr. Elizabeth Woodward, University of Toronto Resident in Psychiatry In broad terms, substance use disorders occur when a substance is used in a compulsive manner with a lack of control over
More informationTobacco smoking is the leading preventable. Varenicline Versus Bupropion SR or Placebo for Smoking Cessation: A Pooled Analysis
Varenicline Versus Bupropion SR or Placebo for Smoking Cessation: A Pooled Analysis Mitchell Nides, PhD; Elbert D. Glover, PhD, FAAHB; Victor I. Reus, MD; Arden G. Christen, DDS, MSA, MA; Barry J. Make,
More informationMood Disorders and Addictions: A shared biology?
Mood Disorders and Addictions: A shared biology? Dr. Paul Stokes Clinical Senior Lecturer, Centre for Affective Disorders, Department of Psychological Medicine Disclosures No relevant disclosures: No paid
More informationUpdates in the Treatment of Tobacco Use Disorder
Updates in the Treatment of Tobacco Use Disorder PCSS-MAT; Smoking Cessation Leadership Center and American Psychiatric Association Jill M Williams, MD Professor Psychiatry Director, Division Addiction
More informationEfficacy of Varenicline for Smoking Cessation between Smokers with and without Psychiatric Disorders: A 12-week Observational Study
Research Efficacy of Varenicline for Smoking Cessation between Smokers with and without Psychiatric Disorders: A 12-week Observational Study Han-Ting Wei 1,2,, Wei-Chen Lin 2,3, Ying-Sheue Chen 2,3, Ying-Chiao
More informationMotivating Smoking Cessation: Recognizing and Capitalizing on Teachable Moments
Motivating Smoking Cessation: Recognizing and Capitalizing on Teachable Moments Belinda Borrelli, PhD Professor & Director, The Miriam Hospital and Brown Medical School, Program in Nicotine and Tobacco
More informationState of the Science in the treatment of nicotine dependence Terry A. Rustin, M.D.
State of the Science in the treatment of nicotine dependence 2006 Terry A. Rustin, M.D. State of the Science Public health issues Effects of nicotine Smoking cessation New chemotherapeutic agents Nicotine
More informationPFIZER INC. THERAPEUTIC AREA AND FDA APPROVED INDICATIONS: See USPI.
PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. For publications based on this study, see associated bibliography.
More informationOver the Road Truck Driver Who Smokes
Continuing Medical Education Case Presentation 1 CME Credit Physicians Physician Assistants Nurse Practitioners Over the Road Truck Driver Who Smokes RELEASE & REVIEW DATE This activity was last reviewed
More informationMedication Management to Aid in Smoking Cessation. Rachel Constant, Pharm.D. Baptist Health Corbin Pharmacy Resident 3/22/2019
Medication Management to Aid in Smoking Cessation Rachel Constant, Pharm.D. Baptist Health Corbin Pharmacy Resident 3/22/2019 1 Learning Objectives: Review the prevalence of tobacco use. Describe tools
More informationVarenicline and cardiovascular and neuropsychiatric events: Do Benefits outweigh risks?
Varenicline and cardiovascular and neuropsychiatric events: Do Benefits outweigh risks? Sonal Singh M.D., M.P.H, Johns Hopkins University Presented by: Sonal Singh, MD MPH September 19, 2012 1 CONFLICTS
More informationTobacco Cessation: Priority for Health Providers. Acknowledgements. Tobacco Cessation: Secondhand Smoke. Smoke-Free Environment & CA
Acknowledgements Smoking Cessation Leadership Center http://smokingcessationleadership.ucsf.edu/ Rx for Change http://rxforchange.ucsf.edu/ Tobacco Use and Dependence: 2008 Update http://www.surgeongeneral.gov/tobacco
More informationDisclaimers. Smoking and Smoking Cessation. Worldwide. Objectives. Statistics at Home. Smoking Epidemic 16/10/2017
Disclaimers Smoking and Smoking Cessation Dr. Janneke Gradstein CCFP(EM) Yarmouth, NS Received CHA Funding 6 th Annual Ottawa Conference: State of the Art Clinical Approaches to smoking cessation. References
More informationAn Evidence-based Approach to Address Tobacco Dependence Treatment in Mental Health and Addictions Settings
University of Kentucky UKnowledge Nursing Presentations College of Nursing 11-2011 An Evidence-based Approach to Address Tobacco Dependence Treatment in Mental Health and Addictions Settings Chizimuzo
More informationRimonabant for treating tobacco dependence
REVIEW Rimonabant for treating tobacco dependence Michael B Steinberg 1,2 Jonathan Foulds 1 1 University of Medicine and Dentistry of New Jersey School of Public Health, Tobacco Dependence Program, New
More information7 DAY QUIT SMOKING CHALLENGE 7 DAY QUIT SMOKING CHALLENGE 7 DAY QUIT SMOKING PDF YOU CAN QUIT SMOKING. QUIT SMOKING CDC 1 / 5
7 DAY QUIT SMOKING PDF YOU CAN QUIT SMOKING. QUIT SMOKING CDC 1 / 5 2 / 5 3 / 5 7 day quit smoking pdf 7 Your guide to quitting smoking This guide is for smokers who want to quit and stay quit. Just like
More informationTobacco & Nicotine: Addiction and Treatment
Tobacco & Nicotine: Addiction and Treatment Tim McAfee, MD, MPH Chief Medical Officer - Free & Clear 206-876-2551 - tim.mcafee@freeclear.com Affiliate Assistant Professor, University of Washington, School
More informationTobacco Dependence Screening and Treatment in Behavioral Health Settings. Prescribing
Tobacco Dependence Screening and Treatment in Behavioral Health Settings Prescribing GOAL To build the capacity of prescribing clinicians in behavioral health settings to integrate best practices for prescribing
More informationNicotine Replacement Therapy, Zyban and Champix. Name of presentation
Nicotine Replacement Therapy, Zyban and Champix Nicotine Replacement Therapy (NRT) - Rationale for use Nicotine is highly addictive and causes unpleasant withdrawal symptoms which often undermine a quit
More informationSmoking Cessation A Clinicians Perspective. Jeff Wilson, MD
Smoking Cessation A Clinicians Perspective Jeff Wilson, MD Overview Tobacco control what we have accomplished and the road ahead Role of the health care professional Using pharmacotherapy Electronic cigarettes
More informationCore Competencies - Smoking Cessation Fundamentals
Core Competencies - Smoking Cessation Fundamentals This training standard was developed for the National Training Service (NTS) Alliance in consultation with subject matter experts. The purpose of this
More informationWanting to Get Pregnant
Continuing Medical Education COPD Case Presentation LEARNING OBJECTIVES Those completing this activity will receive information that should allow them to Assist a patient in developing a quit plan; Advise
More informationTreatment of Tobacco and Cocaine Use Disorders
Treatment of Tobacco and Cocaine Use Disorders A. Eden Evins, MD, MPH Director, Center for Addiction Medicine Massachusetts General Hospital Associate Professor of Psychiatry Harvard Medical School A.
More informationOutpatient Tobacco Addiction Treatment Pathway Additional Notes
Outpatient Tobacco Addiction Treatment Pathway Additional Notes First Line: Varenicline (provide in conjunction with counselling/support, but if such support is refused or is not available, this should
More informationTobacco Basics and Brief Cessation Interventions. Prepared by: Margie Kvern, RN, MN Diane Mee, RN, BN October 2014
Tobacco Basics and Brief Cessation Interventions Prepared by: Margie Kvern, RN, MN Diane Mee, RN, BN October 2014 Outline Tobacco Basics WRHA Clinical Practice Guideline for Management of Tobacco Use and
More informationEvidence-based Practice
Evidence-based Practice Michael V. Burke, EdD Assistant Professor of Medicine Treatment Program Coordinator Mayo Clinic Nicotine Dependence Center May, 2013 Learning objectives At the end of this presentation
More information5. Offer pharmacotherapy to all smokers who are attempting to quit, unless contraindicated.
0 11 Key Messages 1. Ask and document smoking status for all patients. 2. Provide brief advice on quit smoking at every visit to all smokers. 3. Use individual, group and telephone counselling approaches,
More informationWANTED. Pharmacists to Help Patients Quit Smoking: Best practices and updates in cessation treatment. Robin Corelli, PharmD
WANTED Pharmacists to Help Patients Quit Smoking: Best practices and updates in cessation treatment Robin Corelli, PharmD UCSF School of Pharmacy Karen Hudmon, DrPH, MS, RPh Purdue University College of
More informationPage 1 of 7 INITIAL EVALUATION MANAGEMENT. STATUS Yes. See page 2. Refer patient to a tobacco treatment program 3 (preferred) Patient interested?
Page 1 of 7 INITIAL EVALUATION Screen current tobacco use status Has patient smoked more than 100 cigarettes in lifetime? Has patient smoked or used tobacco in the last 12 months? STATUS Within the last
More information1. Describe the benefits of smoking cessation. 2. List the withdrawal symptoms of quitting smoking. Cessation
Time to Butt Out Adil Virani, BSc (Pharm), Pharm D, FCSHP Objectives After this presentation, participants should be able to: 1. Describe the benefits of smoking cessation 2. List the withdrawal symptoms
More informationBy John P. Sader MD, ASAM certified, ABAM Diplomate Campbellton, NB October 2017
By John P. Sader MD, ASAM certified, ABAM Diplomate Campbellton, NB October 2017 NRT = Nicotine Replacement Therapy: Patches 21 mg/14 mg/7 mg Gum 2 mg/4 mg Lozenges 1 mg/2 mg (Thrive) and 2 mg/4 mg (Nicorette)
More informationPL CE LIVE February 2011 Forum
February 2011 PL CE LIVE Kristin W. Weitzel, Pharm.D., CDE, FAPhA Associate Editor and Director of Editorial Projects Pharmacist s Letter/Prescriber s Letter Atypical Antipsychotics Atypical Antipsychotics
More informationThe 5A's are practice guidelines on tobacco use prevention and cessation treatment (4):
Smoking Cessation Module Tobacco use is the single greatest preventable cause of chronic diseases and premature deaths worldwide. The Canadian Cancer Society reports that tobacco product use is responsible
More informationStriving for Success: Smoking Cessation Strategies among people with Mental Illness
Striving for Success: Smoking Cessation Strategies among people with Mental Illness Carlo C. DiClemente, Ph.D. Director of Professor, University of Maryland, Baltimore County October 15, 2011 NAMI Workshop
More informationFormulary and Prescribing Guidelines
Formulary and Prescribing Guidelines SECTION 17: NICOTINE REPLACEMENT THERAPY 17.1 Introduction These guidelines should be used in conjunction with SEPT No Smoking Policy (HRP20) and for service users
More informationLearning Objectives 4/3/2018 UP IN SMOKE: NAVIGATING THE CHANGING LANDSCAPE OF SMOKING CESSATION BACKGROUND
UP IN SMOKE: NAVIGATING THE CHANGING LANDSCAPE OF SMOKING CESSATION Richard Dang, PharmD, APh, BCACP Assistant Professor of Clinical Pharmacy, USC School of Pharmacy Rory Kim, PharmD, BCACP Assistant Professor
More informationECHO Clinics. Schedule and Curriculum Topics. Tuesdays 12:00 1:00 pm. Date Topic Presenter. Cessation: An Overview Part 2
ECHO Clinics Schedule and Curriculum Topics Tuesdays 12:00 1:00 pm Date Topic Presenter Tuesday, September 19, 2017 Cessation: An Overview Part 1 Tuesday, September 26, 2017 Neurobiology of Nicotine Dependence
More informationImportance of smoking cessation in improving the physical and mental health of people with mental illness
Importance of smoking cessation in improving the physical and mental health of people with mental illness Dr Jonathan Campion Director of Public Mental Health and Consultant Psychiatrist South London and
More informationSmoking Cessation Strategies for the 21st Century
Transcript Details This is a transcript of an educational program accessible on the ReachMD network. Details about the program and additional media formats for the program are accessible by visiting: https://reachmd.com/programs/lipid-luminations/smoking-cessation-strategies-for-the-21stcentury/3862/
More information